Azitra Inc(US:AZTR)2025-05-13 21:05Financial Performance - For Q1 2025, Azitra reported a net loss of $3.1 million, compared to a net loss of $2.9 million in Q1 2024, reflecting a year-over-year increase of approximately 6.9%[9] - General and Administrative (G&A) expenses increased to $1.9 million in Q1 2025, up 26.8% from $1.5 million in Q1 2024[9] - Total operating expenses for Q1 2025 were $3.1 million, compared to $3.0 million in Q1 2024, indicating a slight increase of 4.7%[9] Research and Development - Research and Development (R&D) expenses for Q1 2025 were $1.3 million, a decrease of 13.3% from $1.5 million in the same period of 2024[9] - Azitra plans to provide initial safety data from the Phase 1b trial for ATR-12 by mid-2025, with topline results expected by year-end 2025[4] - The company anticipates dosing the first patient in the Phase 1/2 trial for ATR-04 by mid-2025, targeting EGFRi-associated rash affecting approximately 150,000 patients annually in the U.S.[4] Funding and Capital - Azitra entered into a Purchase Agreement for up to $20 million with Alumni Capital LP to fund its clinical pipeline[5] - The company closed two public offerings, raising a total of $2.2 million[5] Cash Position - As of March 31, 2025, cash and cash equivalents stood at $3.2 million, down from $4.6 million at the end of 2024[9] Technology and Innovation - Azitra's proprietary platform includes a microbial library of approximately 1,500 bacterial strains, enhanced by AI and machine learning technologies[7]